Hiroaki Matsubara, a former Kyoto Prefectural University cardiology researcher who resigned last year following an investigation, has had another paper retracted, his ninth. Here’s the notice from Arteriosclerosis, Thrombosis, and Vascular Biology:
The American Heart Association (AHA) is retracting five studies by Hiroaki Matsubara, a former Kyoto Prefectural University cardiology researcher, that it had subjected to an expression of concern last year. Here’s the notice:
Hiroaki Matsubara, a leading Japanese cardiology researcher who has had three papers retracted and another five subject to expressions of concern, has resigned from Kyoto Prefectural University, according to local media. Mainichi Shimbun reports — according to our roughest of (Google) translations — that Kyoto Prefectural University accepted Matsubara’s resignation following an investigation. That investigation … Continue reading After three retractions, five expressions of concern, cardiologist Matsubara resigns post
The American Heart Association, which publishes a number of journals, has issued an Expression of Concern about five papers in three of their publications, following allegations of image manipulation. All of the papers include Hiroaki Matsubara, of Kyoto Prefectural University, as a co-author. The notice begins: It has come to the attention of the American … Continue reading Five papers by prominent cardiologist Hiroaki Matsubara subject to Expression of Concern
Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, we could really use your help. Would you consider a tax-deductible donation to support Weekend Reads, and our daily work? Thanks in advance. The week at Retraction Watch featured: Researchers suing a journal over a retraction; A publisher retracting … Continue reading Weekend reads: Leading stem cell researcher’s work under scrutiny; faked drug trial data; troubling China practice snares publisher
A second paper about a major randomized trial in Japanese patients with heart disease is being retracted, after an investigation reportedly found multiple problems with the paper. As predicted by Pharma Japan, Hypertension Research is retracting a 2011 paper, already the subject of two errata. Although a spokesperson said she couldn’t say why the paper was being retracted, as … Continue reading Second paper about major blood pressure drug trial in Japan to be retracted
A major scandal in Japan over the Novartis hypertension drug valsartan has resulted in a retraction from the Journal of Human Hypertension. Frequent Retraction Watch subject Hiroaki Matsubara resigned his post at Kyoto Prefectural University in 2013, after his work on valsartan was shown to be riddled with data errors and undisclosed conflicts of interest. Also that year, … Continue reading Can’t spell Novartis without VART: Drug study retracted for conflict of interest, data issues
The Lancet has retracted a study of Novartis’ blood pressure drug valsartan (Diovan) that has been subject to an investigation following the retraction of a related study earlier this year.
Hiroaki Matsubara, a prominent cardiologist with five Expressions of Concern and two retractions for his CV, has another retraction. As Larry Husten, who first reported the retraction at Forbes, notes, the notice for 2009’s “Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study,” which appeared in … Continue reading Study of blood pressure drug valsartan retracted
The Circulation Journal, the official organ of the Japanese Circulation Society, is retracting two papers by Hiroaki Matsubara, lead researcher on the Kyoto Heart Study, for unreliable findings. Matsubara’s institution, Kyoto Prefectural University, confirmed to us last March that it was investigating the prominent cardiologist. The work of Matsubara came into question last year when … Continue reading Journal retracts two papers by Japanese cardiologist under investigation